34 completed. 34 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 34 |
| Phase 2 | 2 | Completed 2 |
Follow Fluconazole: new trials by email Literature Review of Fluconazole trials Research Report on Fluconazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Prophylactic Fluconazole Therapy in Preterm and Very Low Birth Weight Neonates in Preventing Invasive Fungal Infection. Fluconazole, Saline - Invasive Candidiases | Phase 3 | Completed | Services Institute of Medical Sciences, Pakistan | 110 | 2021-05-01 | 2023-05-08 |
| Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Rezafungin for Injection, Posaconazole, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Mundipharma Research Limited | 602 | 2020-05-11 | 2026-04-13 |
| Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) Fluconazole Tablet, IBREXAFUNGERP, Placebo oral tablet - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Scynexis, Inc. | 440 | 2019-10-21 | 2023-06-18 |
| Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections Oteseconazole (VT-1161) 150mg capsule, Fluconazole 150mg capsule, Placebo - Recurrent Vulvovaginal Candidiasis | Phase 3 | Completed | Mycovia Pharmaceuticals Inc. | 219 | 2019-03-13 | 2022-02-04 |
| Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Rezafungin for Injection, Caspofungin, Fluconazole - Candidemia, Mycoses | Phase 3 | Completed | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 199 | 2018-10-07 | 2023-01-06 |
| Fluconazole Versus Micafungin in Neonates With Candidiasis Fluconazole, Micafungin - Candidiasis | Phase 2 / Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 100 | 2014-10-01 | 2025-09-04 |
| Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy Raltegravir, Fluconazole, Azithromycin - Human Immunodeficiency Virus | Phase 3 | Completed | Anna Griffiths, MRC | 1805 | 2013-06-01 | 2016-04-20 |
| Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Fungal Infection, Hematopoietic and Lymphoid Cell Neoplasm | Phase 3 | Completed | Children's Oncology Group | 292 | 2013-03-21 | 2024-10-16 |
| The Study Of Fluconazole For Vulvovaginal Candidiasis Fluconazole - Vulvovaginal Candidiasis | Phase 3 | Completed | Pfizer | 157 | 2013-03-05 | 2021-07-19 |
| Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge Fluconazole and Secnidazole - Vaginal Discharge | Phase 3 | Completed | Universidad Nacional de Colombia | 118 | 2012-05-01 | 2014-04-11 |
| Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Caspofungin Acetate, Fluconazole, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Adult Acute Monoblastic Leukemia | Phase 3 | Completed | Children's Oncology Group | 517 | 2011-04-04 | 2021-03-30 |
| Liver Transplant European Study Into the Prevention of Fungal Infection micafungin, fluconazole, liposomal amphotericin B - Liver Transplantation, Mycoses | Phase 3 | Completed | Astellas Pharma Inc | 350 | 2009-12-15 | 2024-11-18 |
| Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis Anidulafungin, Fluconazole - Candidemia | Phase 3 | Completed | Pfizer | 70 | 2009-02-01 | 2019-04-04 |
| Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED) Posaconazole, Fluconazole - Leukopenia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 252 | 2008-11-01 | 2017-04-07 |
| Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight fluconazole, placebo - Candidiasis | Phase 3 | Completed | Daniel Benjamin | 362 | 2008-11-01 | 2019-03-01 |
| Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures Metronidazole, Cefuroxime, Amoxicillin (+ clavulanic acid) and Fluconazole, Placebo - Acute Appendicitis, Perforated Gastroduodenal Ulcer | Phase 3 | Completed | The Faculty Hospital Na Bulovce | 187 | 2008-07-01 | 2012-02-08 |
| Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Anidulafungin, Fluconazole, Voriconazole - Invasive Candidiasis | Phase 3 | Completed | Pfizer | 216 | 2008-07-01 | 2011-05-30 |
| POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED) Posaconazole, Fluconazole - Coccidioidomycosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 16 | 2007-05-01 | 2017-04-11 |
| Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia Micafungin, fluconazole - Invasive Candidiasis, Candidemia | Phase 3 | Completed | Astellas Pharma Inc | 24 | 2004-08-01 | 2008-01-02 |
| Diabetes Mellitus and Vulvovaginal Candidiasis Boric, Fluconazole - Diabetes Mellitus, Vulvovaginal Candidiasis | Phase 3 | Completed | Indian Council of Medical Research | 100 | 2004-06-01 | 2008-05-22 |
Showing 20 of 34. Sign in to see all of them.
Candidiasis (9) · Mycoses (9) · Candidiasis, Invasive (7) · Candidemia (6) · HIV Infections (6) · Acquired Immunodeficiency Syndrome (5) · Candidiasis, Vulvovaginal (4) · Infections (4) · Invasive Fungal Infections (4) · Fungemia (3) · AIDS-Related Opportunistic Infections (2) · Candidiasis, Oral (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Neoplasms (2)
Pfizer (9) · Astellas Pharma Inc (3) · Children's Oncology Group (2) · Merck Sharp & Dohme LLC (2) · Anna Griffiths, MRC (1) · Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Daniel Benjamin (1) · Fred Hutchinson Cancer Center (1) · Indian Council of Medical Research (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Medical College of Wisconsin (1) · Mundipharma Research Limited (1) · Mycovia Pharmaceuticals Inc. (1) · National Cancer Institute (NCI) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (20) · Italy (6) · Belgium (5) · Canada (5) · France (5) · Spain (5) · Germany (4) · United Kingdom (4) · Greece (3) · Russia (3) · Taiwan (3) · Austria (2) · Brazil (2) · Colombia (2) · Czechia (2)
Andrea E Rodriguez, MD, MsC (1) · Ariel I Ruiz, MD, MsC (1) · Armstrong D (1) · Arnold M. Markoe, MD, ScD (1) · Bozzettee S (1) · Christopher C Dvorak (1) · Daniel K Benjamin, MD MPH PhD (1) · Diana M Gibb (1) · Dismukes W (1) · Edith Muller, M.D (1) · Jorge A Rubio, M.D., MsC (1) · Kieren A. Marr, MD (1) · Laura Cox, PhD (1) · M Tauseef Omer, MBBS FCPS Pediatrics (1)
PMID 33438477, PMID 17568028, PMID 19915602, PMID 20826719, PMID 23924680, PMID 23943184, PMID 23959319, PMID 24794367, PMID 25520332, PMID 25887336, PMID 28459966, PMID 28597967, PMID 29653915, PMID 29744900, PMID 30418357, PMID 30513108, PMID 31280481, PMID 31688884, PMID 32032174, PMID 32103268, PMID 33136159, PMID 33891293, PMID 34432828, PMID 36396498, PMID 36442484, PMID 37773627, PMID 38008099, PMID 38502709, PMID 38985561, PMID 39259571, PMID 39468640, PMID 39529079, PMID 41194465, PMID 41940006
2008 (2), U10CA095861 (2), UG1CA189955 (2), 2017 (1), R01HD057956 (1), U01HL069294 (1), U24CA076518 (1)